Causes for Treatment Delays in Dystonia and Hemifacial Spasm: A Canadian Survey
Authors:
Open Access
- 1 January 2011
- journal article
- research article
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 38 (5) , 704-711
Abstract
Background: Dystonia must be accurately diagnosed so that treatment can be administered promptly. However, dystonia is a complex disorder, with variable presentation, which can delay diagnosis.Methods: Data were gathered by questionnaire from 866 patients with dystonia or hemifacial spasm (HFS) treated in 14 movement disorders centres in Canada injecting botulinum toxin, to better understand the path to diagnosis, wait times and obstacles to treatment.Results: Most participants were female (64.1%), mean age was 58 years, and patients consulted an average of 3.2 physicians before receiving a dystonia or HFS diagnosis. Many patients (34%) received other diagnoses before referral to a movement disorders clinic, most commonly “stress” (42.7%). A variety of treatments were often received without a diagnosis. The mean lag time between symptom onset and diagnosis was 5.4 years. After the decision to use botulinum toxin, patients waited a mean of 3.1 months before treatment. The most common diagnoses were cervical dystonia (51.6% of patients), HFS (20.0%) and blepharospasm (9.8%).Conclusions: Survey results show that diagnosis of dystonias or of HFS, and therefore, access to treatment, is delayed. An educational program for primary care physicians may be helpful to decrease the time to diagnosis and referral to a specialist centre for treatment.Keywords
This publication has 20 references indexed in Scilit:
- The clinical approach to movement disordersNature Reviews Neurology, 2010
- Treatment of hyperkinetic movement disordersThe Lancet Neurology, 2009
- Is this dystonia?Movement Disorders, 2009
- Update on blepharospasmNeurology, 2008
- Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystoniaNeurologic Clinics, 2008
- Prevalence of cervical dystonia and spasmodic torticollis in the United States general populationParkinsonism & Related Disorders, 2007
- Botulinum toxin in the treatment of blepharospasm and hemifacial spasmJournal of Neural Transmission, 2007
- The clinical expression of primary dystoniaJournal of Neurology, 2003
- BlepharospasmNeurology, 2002
- Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, MinnesotaMovement Disorders, 1995